R Strickland
Internal Medicine · Bucyrus, OHNPI 1205822871
Payments from drug & device makers
Across 216 payments — averaging $15.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$637
- AstraZeneca$441
- Amgen$331
- GSK$296
- Novartis$249
- Pfizer$181
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,392100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $637 |
| AstraZeneca | 23 | $441 |
| Amgen | 21 | $331 |
| GSK | 19 | $296 |
| Novartis | 18 | $249 |
| Pfizer | 12 | $181 |
| Axsome Therapeutics, Inc. | 4 | $165 |
| Lilly USA, LLC | 11 | $165 |
| Boehringer Ingelheim | 9 | $121 |
| Amarin Pharma, Inc. | 7 | $95 |
| Lundbeck LLC | 5 | $81 |
| Esperion Therapeutics, Inc. | 4 | $73 |
| Merck | 5 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $67 |
| Novo Nordisk | 4 | $59 |
| Bayer | 2 | $48 |
| Eisai Inc. | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Johnson & Johnson | 2 | $27 |
| Mylan Specialty L.p. | 2 | $25 |
| Avanir Pharmaceuticals, Inc. | 2 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$103
How this compares
$3,392 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $64,052 |
| EliquisApixaban | 62 | $52,746 |
| MounjaroTirzepatide | 35 | $51,644 |
| FarxigaDapagliflozin Propanediol | 61 | $51,050 |
| JardianceEmpagliflozin | 47 | $38,292 |
| VascepaIcosapent Ethyl | 66 | $36,888 |
| Spiriva RespimatTiotropium Bromide | 30 | $18,666 |
| JanuviaSitagliptin Phosphate | 15 | $15,342 |
| MyrbetriqMirabegron | 21 | $13,930 |
| XareltoRivaroxaban | 17 | $13,335 |
| RybelsusSemaglutide | 14 | $13,156 |
| Repatha SureclickEvolocumab | 20 | $10,863 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,780 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $10,314 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $296 | $85,146121 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $121 | $63,56490 claims |
| PfizerEliquis | $181 | $52,74662 claims |
| Lilly USA, LLCMounjaro | $165 | $51,64435 claims |
| AstraZenecaFarxiga | $441 | $51,05061 claims |
| MerckJanuvia | $68 | $15,34215 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $13,93021 claims |
| Johnson & JohnsonXarelto | $27 | $13,33517 claims |
| Novo NordiskRybelsus | $59 | $13,15614 claims |
| AbbVieSynthroid | $637 | $97015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Bucyrus
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
- Narinder SainiSpringfield$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.